CRISPR technology could one day create “designer babies, ” raising major ethical and social inequality concerns.

An experimental gene-editing therapy developed by Crispr Therapeutics is showing promise for treating heart disease.

In a highly anticipated article, FDA officials Vinay Prasad, M.D., and Martin Makary, M.D., outlined a novel regulatory ...

Explore CRISPR technology explained, gene editing science, DNA modification, and genetic engineering ethics—discover how ...

One dose of an experimental drug cover offer lifetime treatment for people with high cholesterol, but its long-term safety is ...

An experimental gene-editing treatment shows promise for permanently lowering levels of cholesterol and triglycerides, ...

In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol ...

The approach is “very exciting,” but one expert says a lot more research is needed, especially around safety, before clinical ...

Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, today announced it has entered into a patent license agreement with Shandong ...

In a Phase 1, first-in-human trial, a one-time infusion of an investigational CRISPR-Cas9 therapy targeting angiopoietin-like protein 3 (ANGPTL3) was safe and reduced LDL cholesterol by nearly 50% and ...

Scientists at The University of Texas at Austin have developed a revolutionary gene-editing method using bacterial retrons that can correct multiple disease-causing mutations at once. Unlike ...

Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ...